Literature DB >> 2040715

Alprazolam levels and response in panic disorder: preliminary results.

M Z Wincor1, D J Munjack, R Palmer.   

Abstract

Fifty-five young adult patients completed a study comparing alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. Twenty completed 5 weeks of treatment with alprazolam. No concomitant psychological treatment was administered. Plasma alprazolam levels were determined at baseline and at the end of the trial by means of automated gas chromatography. These levels were significantly correlated with dose (p = 0.001). Dividing the data into quartiles based on alprazolam concentration, no direct, linear relationship was found between alprazolam levels and response (as defined by a criterion of zero panic attacks). However, analysis of the combined middle two quartiles versus the combined upper and lower quartiles showed a positive trend toward a curvilinear relationship; i.e., there was a greater response rate within the 18-62 ng/ml concentration range than in the combined 0-17 plus 63-107 ng/ml range, (chi 2 = 2.4; p = 0.12). The findings are very preliminary in nature. It remains to be seen if the results will reach significance with a large sample size and a more tightly controlled study design.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2040715

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  3 in total

Review 1.  Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.

Authors:  B E Laurijssens; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of alprazolam. Therapeutic implications.

Authors:  D J Greenblatt; C E Wright
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

3.  A Case Report of Clonazepam Dependence: Utilization of Therapeutic Drug Monitoring During Withdrawal Period.

Authors:  Ivana Kacirova; Milan Grundmann; Petr Silhan; Hana Brozmanova
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.